Zeliox, an Iranian-made oral drug containing resmetirom, is transforming fatty liver treatment by offering an effective, locally produced alternative to costly imports. With full regulatory approval, domestic API production, and proven clinical impact on reducing liver fat, inflammation, and the progression of fibrosis, the drug is priced at under USD 2 per tablet, compared to USD 180 for foreign versions. Zeliox significantly improves patient access, reduces treatment costs, and marks a major step toward self-reliance in Iran’s pharmaceutical industry.
December 06, 2025
0
39195
